Navigation Links
Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
Date:9/21/2009

CAMBRIDGE, Mass., Sept. 21 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., announced today that Clet Niyikiza, Ph.D., has joined the company as Senior Vice President, Development. Dr. Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) where he was Vice President and Medicine Development Leader for oncology. Dr. Niyikiza has extensive drug development experience with a career that spans over 18 years in the pharmaceutical industry in which he has led ten New Drug Application teams that have all successfully obtained approvals from U.S. and European regulatory authorities.

"Merrimack is founded on a systems biology approach to drug discovery and development," says Merrimack President and CEO Robert Mulroy. "Clet's experience couples a leading knowledge of oncology drug development with a passion for systems approaches to medicine which make him an excellent leader for our teams working on a pipeline of very exciting oncology therapeutics."

A mathematician by training, Dr. Niyikiza began his pharmaceutical career at Eli Lilly and Company, focusing on applying systems techniques to better understand disease and drug interactions. During his tenure at Lilly, Dr. Niyikiza was credited for playing critical roles in developing many medicines, including two popular anticancer therapies. Dr. Niyikiza used a systems biology approach to identify the previously unknown role of a blood marker which was causing life-threatening toxicities for one of the therapies. The discovery allowed for the successful development of the therapeutic for multiple indications in cancer and was featured on the front page of the The Wall Street Journal in 2004.

"The Network Biology approach of understanding the intricate underlying mechanisms of a disease first and then designing a drug based on those complexities has the potential to be hugely beneficial to patients," says Dr. Niyikiza. "It is that possibility that brought me to Merrimack and makes MM-121 and MM-111 such promising oncology therapeutic candidates."

Prior to GSK, Dr. Niyikiza held the position of Lilly Research Fellow and Global Oncology Pharmacogenomics Leader at Eli Lilly. He has also worked with Syntex Research and as a Visiting Professor of Mathematics with Indiana University. Dr. Niyikiza received his Doctorate and Masters degrees from Indiana University and a Masters from the African Institute of Statistics and Applied Economics in Kigali, Rwanda.

About Merrimack

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111, are currently in clinical development. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and well-tolerated therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts.


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
4. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
5. Sunesis Pharmaceuticals Receives NASDAQ Notification
6. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
7. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
8. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
9. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
10. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
11. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):